These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12523918)

  • 21. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of intensive long-term treatment of familial hypercholesterolemia.
    Retterstøl K; Stugaard M; Gørbitz C; Ose L
    Am J Cardiol; 1996 Dec; 78(12):1369-74. PubMed ID: 8970408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
    Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
    Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
    J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
    Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
    Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective screening for familial hypercholesterolemia in Austrian children - first year results.
    Kreissl A; Walleczek N; Espina PR; Hallwirth U; Greber-Platzer S
    BMC Pediatr; 2019 Jun; 19(1):208. PubMed ID: 31238984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
    Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
    Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
    J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
    Gagné C; Bays HE; Weiss SR; Mata P; Quinto K; Melino M; Cho M; Musliner TA; Gumbiner B;
    Am J Cardiol; 2002 Nov; 90(10):1084-91. PubMed ID: 12423708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
    Sijbrands EJ; Lombardi MP; Westendorp RG; Leuven JA; Meinders AE; Van der Laarse A; Frants RR; Havekes LM; Smelt AH
    Atherosclerosis; 1998 Feb; 136(2):247-54. PubMed ID: 9543095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
    Illingworth DR
    Ann Intern Med; 1984 Nov; 101(5):598-604. PubMed ID: 6567462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
    Razek O; Cermakova L; Armani H; Lee T; Francis GA; Mancini GBJ; Frohlich J; Brunham LR
    Can J Cardiol; 2018 Aug; 34(8):1004-1009. PubMed ID: 30056842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.